Dirk Zboralski
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Preclinical Development of 3BP-3940, a Fibroblast Activation Protein-Targeted Cyclic Peptide-Based Radiotheranostic for Imaging and Therapy.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 14, 2025
Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX.
Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 27, 2023
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 31, 2023
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 15, 2022
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 28, 2020
Generation and Harnessing of Heterotypic Tumor-Stroma Spheroids to Study Cancer Immunosurveillance.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: November 23, 2018
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Journal: Leukemia
Published: January 12, 2017
Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade.
Journal: Cancer immunology research
Published: November 01, 2016
Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes sphingosine 1-phosphate, a central mediator of angiogenesis.
Journal: The Biochemical journal
Published: May 17, 2014
SDF-1 inhibition targets the bone marrow niche for cancer therapy.
Journal: Cell reports
Published: January 23, 2014
Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats.
Journal: Neuro-oncology
Published: December 17, 2013
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.
Journal: Blood
Published: November 27, 2013
Last Updated: 09/26/2026